What is Lifesci Capital's Forecast for AVBP Q2 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2025 EPS estimates for ArriVent BioPharma in a research report issued to clients and investors on Monday, June 23rd. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($0.75) per share for the quarter. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.66) EPS.

A number of other equities research analysts have also recently issued reports on AVBP. Guggenheim reissued a "buy" rating and issued a $45.00 target price on shares of ArriVent BioPharma in a research report on Tuesday. B. Riley initiated coverage on shares of ArriVent BioPharma in a research report on Thursday, March 20th. They set a "buy" rating and a $37.00 price objective for the company. Jones Trading initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a "buy" rating and a $40.00 price objective for the company. Oppenheimer reaffirmed an "outperform" rating and set a $44.00 price objective (up previously from $39.00) on shares of ArriVent BioPharma in a research report on Tuesday. Finally, Wall Street Zen cut shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.

ArriVent BioPharma Stock Up 0.4%

Shares of ArriVent BioPharma stock traded up $0.10 during trading on Wednesday, reaching $22.91. The company's stock had a trading volume of 876,062 shares, compared to its average volume of 221,235. The business's 50-day moving average price is $21.66 and its 200-day moving average price is $23.00. The firm has a market cap of $783.75 million, a PE ratio of -6.08 and a beta of 1.26. ArriVent BioPharma has a 52 week low of $15.47 and a 52 week high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($1.24).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of ArriVent BioPharma by 773.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company's stock worth $43,000 after acquiring an additional 1,416 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of ArriVent BioPharma in the fourth quarter worth about $73,000. KLP Kapitalforvaltning AS bought a new position in shares of ArriVent BioPharma in the fourth quarter worth about $83,000. Jane Street Group LLC bought a new position in shares of ArriVent BioPharma in the first quarter worth about $189,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of ArriVent BioPharma by 34.6% in the fourth quarter. New York State Common Retirement Fund now owns 7,783 shares of the company's stock worth $207,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 9.48% of the company's stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.